Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 10/20 | 0.64 |
| ▸ | KCNK9 | Q9NPC2 | 8/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14301092 | 0.90 | SMN1; SMN2 (0.75) | KCNK3KCNK9KCNH2MAPTKDM4E | |
| SCHEMBL14363190 | 0.88 | KCNK3 (0.68) | KCNK3KCNK9KCNH2MAPTKDM4E | |
| SCHEMBL3644692 | 0.85 | KCNK3 (0.71) | KCNK3KCNK9KCNH2MAPTKDM4E | |
| SCHEMBL20083957 | 0.84 | KCNK3 (0.64) | KCNK3KCNK9KCNH2MAPTKDM4E | |
| SCHEMBL12205437 | 0.84 | KCNK3 (0.67) | KCNK3KCNK9KCNH2MAPTKDM4E | |
| SCHEMBL19156955 | 0.81 | KCNK3 (0.66) | KCNK3KCNK9KCNH2KDM4ENPC1 | |
| SCHEMBL4248100 | 0.81 | KCNK3 (0.69) | KCNK3KCNK9KCNH2MAPTKDM4E | |
| SCHEMBL2493233 | 0.80 | KCNK3 (0.68) | KCNK3KCNK9KCNH2NPC1RAB9A | |
| SCHEMBL4248125 | 0.79 | KCNK3 (0.82) | KCNK3KCNK9KCNH2MAPTKDM4E | |
| SCHEMBL12212837 | 0.79 | KCNK3 (0.62) | KCNK3KCNK9KCNH2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | KCNK3 1019/4885KCNK9 1229/4885KCNH2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.